Shots:
- The US Supreme Court has denied Sandoz’ petition to review Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi (etanercept-szzs) for the reference product, Enbrel (etanercept)
- The company was unable to launch the product in the US due to patent litigation. The affordable biosimilar will not be available in the US till 2029 to treat autoimmune and inflammatory diseases
- Erelzi has been approved in the US for more than 4yrs. since Aug’2016
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire
The post The US Supreme Court Denies Sandoz’s Petition for Erelzi (biosimilar, etanercept) first appeared on PharmaShots.
